CG Oncology Reaches New 52-Week High

Analysts Debate Whether the Stock is Still a Buy

Mar. 16, 2026 at 3:33pm

Got story updates? Submit your updates here. ›

CG Oncology, Inc. (NASDAQ:CGON) reached a new 52-week high of $65.71 during trading on Monday. The biopharmaceutical company focused on antibody-based cancer immunotherapies has seen its stock price rise significantly in recent months, prompting debate among analysts on whether it is still a buy at current levels.

Why it matters

CG Oncology's stock performance reflects growing investor optimism around the company's pipeline of cancer drug candidates. As a clinical-stage biotech, the company's future success will depend on the progress and outcomes of its ongoing clinical trials, making its stock price highly sensitive to developments in its research and development efforts.

The details

CG Oncology's stock has risen over 45% since the start of the year, buoyed by a series of positive analyst reports. Several firms, including Morgan Stanley, Royal Bank of Canada, and HC Wainwright, have raised their price targets on the stock, citing the company's promising clinical data and the potential of its antibody-based immunotherapy platform. However, the stock's rapid ascent has also led to concerns that it may be overvalued at current levels.

  • CG Oncology stock reached a new 52-week high of $65.71 on Monday, March 16, 2026.
  • The company posted its latest quarterly earnings results on Friday, February 27, 2026.

The players

CG Oncology, Inc.

A clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers.

Morgan Stanley

A global financial services firm that has set a $93.00 target price on CG Oncology's stock.

Royal Bank of Canada

A multinational financial services company that has raised its price target on CG Oncology to $73.00 and maintained an "outperform" rating on the stock.

HC Wainwright

An investment bank that has increased its price target on CG Oncology to $80.00 and maintained a "buy" rating on the stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.